Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia
Modern therapy of acute myeloid leukemia (AML) began in 1973 with the first report of the successful combination of daunorubicin and cytarabine, which led to complete remission in approximately 45% of patients. Accurate AML diagnosis was dependent on morphology, aided initially only by cytochemistry...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2021-10-01
|
| Serija: | Engineering |
| Teme: | |
| Online pristup: | http://www.sciencedirect.com/science/article/pii/S2095809921003350 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|